羟乙基淀粉 vs 晶体液治疗脓毒血症和感染性休克患者德国 SepNet VISEP 试验结果（英文）课件.pptVIP

下载本文档

7
0
约2.24千字
约 51页
2018-06-23 发布于贵州
举报
版权申诉

羟乙基淀粉 vs 晶体液治疗脓毒血症和感染性休克患者德国 SepNet VISEP 试验结果（英文）课件.ppt

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

羟乙基淀粉 vs 晶体液治疗脓毒血症和感染性休克患者德国 SepNet VISEP 试验结果（英文）课件

3,170 ml HES;Hemodynamic effects;;;;;Effects on renal function;75.00;;;Mean SOFA Score;0.001;;;;VISEP Trial (HES vs. Ringers′ Lactate) - HES 22 ml/kg/BW -;;Progression of mortality from 28 days to 90 days;100;0.003;;0.615;;0.142;Volume resuscitation with HES 10% (200/0.5) results in faster hemodynamic stabilisation. Acute renal failure and need for renal replacement therapy occurred more often in the HES group 28-day mortality is not significantly different between study groups 90-day mortality tends to be higher (33.9% vs 41.0% (p=0.11) in the HES group ;Increasing cumulative dosages of HES are associated with an increase in 90-day mortality. (p=0.0015). Increasing cumulative dosages of HES, but not Ringers′lactate are associated with renal failure and renal replacement therapy; independently from baseline creatinine clearance. ;Increasing cumulative dosages of Ringers′ lactate and HES are associated with an increase in 90-day mortality. This effect is more marked in patients receiving HES (p=0.0015). Increasing cumulative dosages of HES, but not Ringers′lactate are associated with renal failure and renal replacement therapy; independently from baseline creatinine clearance. ;HES 10% (200/0.5) can not be recommended for patients with severe sepsis and other patients at risk for the development of acute renal failure. The safety margin for HES is narrow. Exceeding the recommended upper dose limit (20 ml/kg BW / day) should be avoided. Whether newer HES preparations can be safely used in patients at risk for the development of acute renal failure remains to be elucidated. ;After the results of the VISEP trial were available i.e. Feb.1st 2006 we stopped the use of HES 130/0.4 (Voluven) and replaced it by succinylated gelatin 4%;Impact of change in type of colloid – HES 6 %, 130/04 vs. succinylated Gelatin 4% on resource use costs;Association between change in type of colloid patient morbidity/mortality - HES 6% 130/0.4 vs. Gelatin 4%;Allergic reactions attr